Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.24.1.1.u2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Research and development (“R&D”) expenses, net $ 4,105 $ 4,564
General and administrative expenses 2,680 1,644
Operating loss 6,785 6,208
Other income (88) (91)
Interest expenses 850 565
Loss from change in fair value of Private Placement Warrants 8,010
Finance expense (income), net 1,765 (327)
Loss before tax 17,322 6,355
Tax expenses 5 6
Net loss $ 17,327 $ 6,361
Basic and loss per share of Common Stock (in Dollars per share) $ 0.28 $ 0.2
Weighted average number of shares of Common Stock outstanding, basic (in Shares) 62,292,277 32,125,227